

Julie Bruneau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4063937/publications.pdf>

Version: 2024-02-01

109
papers

5,031
citations

101543

36
h-index

98798

67
g-index

110
all docs

110
docs citations

110
times ranked

5434
citing authors

#	ARTICLE	IF	CITATIONS
1	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <i>Lancet, The</i> , 2019, 394, 1560-1579.	13.7	404
2	Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. <i>BMJ, The</i> , 2012, 345, e5945-e5945.	6.0	363
3	Management of opioid use disorders: a national clinical practice guideline. <i>Cmaj</i> , 2018, 190, E247-E257.	2.0	297
4	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. <i>Addiction</i> , 2018, 113, 545-563.	3.3	242
5	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 153-161.	8.1	231
6	Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. <i>Immunity</i> , 2018, 48, 299-312.e5.	14.3	183
7	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , 2017, 2017, CD012021.	2.8	158
8	Illicit Opioid Use in Canada: Comparing Social, Health, and Drug Use Characteristics of Untreated Users in Five Cities (OPICAN Study). <i>Journal of Urban Health</i> , 2005, 82, 250-266.	3.6	149
9	The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street drug users. <i>Addiction</i> , 2012, 107, 1318-1327.	3.3	149
10	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 1397-1409.	9.1	147
11	Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. <i>Drug and Alcohol Dependence</i> , 2007, 88, 1-8.	3.2	129
12	Early Interferon Therapy for Hepatitis C Virus Infection Rescues Polyfunctional, Long-Lived CD8 ⁺ Memory T Cells. <i>Journal of Virology</i> , 2008, 82, 10017-10031.	3.4	125
13	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 643-657.	3.7	103
14	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. <i>Liver International</i> , 2019, 39, 20-30.	3.9	88
15	Determinants of overdose incidents among illicit opioid users in 5 Canadian cities. <i>Cmaj</i> , 2004, 171, 235-239.	2.0	86
16	Needle exchange, HIV infection, and the politics of science: Confronting Canada's cocaine injection epidemic with participant observation. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2000, 18, 325-350.	1.2	76
17	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. <i>CMAJ Open</i> , 2016, 4, E605-E614.	2.4	74
18	Satellite Needle Distribution Among Injection Drug Users: Policy and Practice in Two Canadian Cities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 98-105.	2.1	67

#	ARTICLE	IF	CITATIONS
19	Sustained Drug Use Changes After Hepatitis C Screening and Counseling Among Recently Infected Persons Who Inject Drugs: A Longitudinal Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 755-761.	5.8	65
20	HIV Protective KIR3DL1/S1-HLA-B Genotypes Influence NK Cell-Mediated Inhibition of HIV Replication in Autologous CD4 Targets. <i>PLoS Pathogens</i> , 2014, 10, e1003867.	4.7	62
21	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. <i>Hepatology</i> , 2013, 57, 2124-2134.	7.3	61
22	Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration. <i>Clinical Infectious Diseases</i> , 2017, 64, 860-869.	5.8	61
23	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , 2018, 62, 14-23.	3.3	58
24	Trends in Human Immunodeficiency Virus Incidence and Risk Behavior Among Injection Drug Users in Montreal, Canada: A 16-Year Longitudinal Study. <i>American Journal of Epidemiology</i> , 2011, 173, 1049-1058.	3.4	56
25	Signatures of Protective Memory Immune Responses During Hepatitis C Virus Reinfection. <i>Gastroenterology</i> , 2014, 147, 870-881.e8.	1.3	56
26	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	3.3	54
27	Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. <i>International Journal of Drug Policy</i> , 2017, 47, 26-33.	3.3	53
28	Global opioid agonist treatment: a review of clinical practices by country. <i>Addiction</i> , 2020, 115, 2243-2254.	3.3	50
29	Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. <i>International Journal of Epidemiology</i> , 2013, 42, 1649-1659.	1.9	48
30	A rapid review of the impacts of "Big Events" on risks, harms, and service delivery among people who use drugs: Implications for responding to COVID-19. <i>International Journal of Drug Policy</i> , 2021, 92, 103127.	3.3	47
31	IL2R β -dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5444-53.	7.1	45
32	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. <i>International Journal of Drug Policy</i> , 2015, 26, 976-983.	3.3	44
33	Comorbid Depression among Untreated Illicit Opiate Users: Results from a Multisite Canadian Study. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 512-518.	1.9	43
34	Patterns of cocaine and opioid co-use and polyroutes of administration among street-based cocaine users in Montréal, Canada. <i>International Journal of Drug Policy</i> , 2013, 24, 142-149.	3.3	43
35	Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. <i>Addiction</i> , 2004, 99, 727-737.	3.3	40
36	Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. <i>International Journal of Drug Policy</i> , 2019, 72, 1-10.	3.3	40

#	ARTICLE	IF	CITATIONS
37	Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs. <i>International Journal of Drug Policy</i> , 2019, 72, 11-23.	3.3	36
38	Associations of substance use patterns with attempted suicide among persons who inject drugs: Can distinct use patterns play a role?. <i>Drug and Alcohol Dependence</i> , 2015, 147, 208-214.	3.2	35
39	A Higher Frequency of NKG2A ⁺ than of NKG2A ^{hi} NK Cells Responds to Autologous HIV-Infected CD4 Cells irrespective of Whether or Not They Coexpress KIR3DL1. <i>Journal of Virology</i> , 2015, 89, 9909-9919.	3.4	35
40	Medication Treatment for Opioid use Disorder and Community Pharmacy: Expanding Care during a National Epidemic and Global Pandemic. <i>Substance Abuse</i> , 2020, 41, 269-274.	2.3	35
41	Epidemiology of Injection Drug Use. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 136-144.	1.9	31
42	The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montr�al, Canada: a modelling study. <i>BMC Infectious Diseases</i> , 2017, 17, 162.	2.9	30
43	Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. <i>Addiction</i> , 2021, 116, 2431-2442.	3.3	30
44	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 72, 1392-1400.	5.8	26
45	Determinants of Antiviral Treatment Initiation in a Hepatitis C-infected Population Benefiting from Universal Health Care Coverage. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 355-361.	1.7	25
46	Association between neighbourhood socioeconomic characteristics and high-risk injection behaviour amongst injection drug users living in inner and other city areas in Montr�al, Canada. <i>International Journal of Drug Policy</i> , 2010, 21, 49-55.	3.3	25
47	High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention. <i>International Journal of Drug Policy</i> , 2017, 47, 61-68.	3.3	24
48	Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. <i>Cmaj</i> , 2019, 191, E462-E468.	2.0	24
49	Injection of drug residue as a potential risk factor for HCV acquisition among Montr�al young injection drug users. <i>Drug and Alcohol Dependence</i> , 2012, 126, 246-250.	3.2	23
50	Time to Seroconversion in HIV-Exposed Subjects Carrying Protective versus Non Protective KIR3DS1/L1 and HLA-B Genotypes. <i>PLoS ONE</i> , 2014, 9, e110480.	2.5	23
51	Estimating the size of the population of persons who inject drugs in the island of Montr�al, Canada, using a six-source capture-recapture model. <i>Drug and Alcohol Dependence</i> , 2014, 142, 174-180.	3.2	23
52	Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 726-739.	7.2	23
53	The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. <i>Contemporary Clinical Trials</i> , 2018, 69, 21-27.	1.8	22
54	The evolving drug epidemic of prescription opioid injection and its association with HCV transmission among people who inject drugs in Montr�al, Canada. <i>Addiction</i> , 2019, 114, 366-373.	3.3	22

#	ARTICLE	IF	CITATIONS
55	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	3.3	22
56	A Prognostic Model for HIV Seroconversion Among Injection Drug Users as a Tool for Stratification in Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 39, 489-495.	2.1	21
57	The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 Collaborative. <i>Clinical Infectious Diseases</i> , 2018, 66, 20-28.	5.8	21
58	Functional analysis of NK cell subsets activated by 721.221 and K562 HLA-null cells. <i>Journal of Leukocyte Biology</i> , 2015, 97, 761-767.	3.3	20
59	Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108135.	3.2	20
60	Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?. <i>International Journal of Drug Policy</i> , 2019, 72, 69-76.	3.3	19
61	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2369-2376.	5.8	19
62	Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107744.	3.2	19
63	Exploring the contingent reality of biomedicine: Injecting drug users, hepatitis C virus and risk. <i>Health, Risk and Society</i> , 2005, 7, 123-140.	1.7	18
64	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. <i>International Journal of Drug Policy</i> , 2015, 26, 1094-1102.	3.3	18
65	Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. <i>International Journal of Drug Policy</i> , 2017, 47, 239-243.	3.3	17
66	Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects. <i>MBio</i> , 2019, 10, .	4.1	17
67	Licit and illicit substance use among people who inject drugs and the association with subsequent suicidal attempt. <i>Addiction</i> , 2015, 110, 1636-1643.	3.3	16
68	HIV-Positive Notification and Behavior Changes in Montreal Injection Drug Users. <i>AIDS Education and Prevention</i> , 2002, 14, 17-28.	1.1	15
69	Anxiety, mood disorders and injection risk behaviors among cocaine users: Results from the COSMO study. <i>American Journal on Addictions</i> , 2015, 24, 654-660.	1.4	15
70	HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric Killer Immunoglobulin-like Receptor (KIR) B motifs; Contribution of KIR B motif encoded genes to NK cell responsiveness. <i>PLoS ONE</i> , 2017, 12, e0185160.	2.5	15
71	Strategies to reduce drug-related harm: responding to the evidence base. <i>Lancet, The</i> , 2019, 394, 1490-1493.	13.7	15
72	Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: Results from a cohort study. <i>International Journal of Drug Policy</i> , 2010, 21, 477-484.	3.3	13

#	ARTICLE	IF	CITATIONS
73	Examining the link between psychological distress, mental health disorders and sharing behaviors among cocaine users. <i>Addictive Behaviors</i> , 2016, 62, 54-59.	3.0	12
74	Examining the link between cocaine bingeing and individual, social and behavioral factors among street-based cocaine users. <i>Addictive Behaviors</i> , 2017, 68, 66-72.	3.0	12
75	Ageing and older people who use illicit opioids, cocaine or methamphetamine: a scoping review and literature map. <i>Addiction</i> , 2022, 117, 2168-2188.	3.3	12
76	The role of living context in prescription opioid injection and the associated risk of hepatitis C infection. <i>Addiction</i> , 2016, 111, 1985-1996.	3.3	11
77	Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention. <i>International Journal of Drug Policy</i> , 2015, 26, 970-975.	3.3	9
78	Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. <i>Journal of Addiction Medicine</i> , 2017, 11, 10-18.	2.6	9
79	Influence of NKG2C Genotypes on HIV Susceptibility and Viral Load Set Point. <i>Journal of Virology</i> , 2021, 95, e0041721.	3.4	9
80	Self-reported impacts of the COVID-19 pandemic among people who use drugs: a rapid assessment study in Montreal, Canada. <i>Harm Reduction Journal</i> , 2022, 19, 38.	3.2	9
81	Association between Binge Drug use and Suicide Attempt among People who Inject Drugs. <i>Substance Abuse</i> , 2018, 39, 315-321.	2.3	8
82	Telehealth for people who inject drugs: An acceptable method of treatment but challenging to access. <i>Journal of Addictive Diseases</i> , 2022, 40, 514-517.	1.3	8
83	Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1413-1422.	2.0	7
84	Association between mental health service utilisation and sharing of injection material among people who inject drugs in Montreal, Canada. <i>Addictive Behaviors</i> , 2019, 96, 175-182.	3.0	7
85	Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs. <i>American Journal of Preventive Medicine</i> , 2020, 58, 845-853.	3.0	7
86	Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. <i>Neuropsychopharmacology</i> , 2021, 46, 2101-2111.	5.4	7
87	Socioeconomic stability is associated with lower injection frequency among people with distinct trajectories of injection drug use. <i>International Journal of Drug Policy</i> , 2021, 94, 103205.	3.3	7
88	The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?. <i>Canadian Liver Journal</i> , 2018, 1, 4-13.	0.9	7
89	Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. <i>Pharmacology Biochemistry and Behavior</i> , 2022, 216, 173376.	2.9	7
90	Prevalence and correlates of prescription opioid residue injection. <i>Drug and Alcohol Dependence</i> , 2016, 166, 69-74.	3.2	6

#	ARTICLE	IF	CITATIONS
91	Gender-specific associations between psychological distress and injecting risk behaviours among people who inject drugs in Montreal, Canada. <i>International Journal of Drug Policy</i> , 2021, 96, 103319.	3.3	6
92	Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial. <i>Addiction</i> , 2022, 117, 2662-2672.	3.3	6
93	Some PWID communities are ready for PrEP, so what's next?. <i>Addiction</i> , 2017, 112, 582-584.	3.3	5
94	Tranquilizer misuse among active cocaine users: Predictors of initiation. <i>Drug and Alcohol Review</i> , 2018, 37, 520-526.	2.1	5
95	SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression. <i>Journal of Hepatology</i> , 2019, 70, e733.	3.7	5
96	Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada. <i>Addiction</i> , 2019, 114, 1495-1503.	3.3	5
97	Deconstructing the "cheque effect": short-term changes in injection drug use after receiving income assistance and associated factors. <i>Addiction</i> , 2021, 116, 571-582.	3.3	5
98	Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada. <i>International Journal of Drug Policy</i> , 2021, 96, 103439.	3.3	5
99	Gender-Specific Situational Correlates of Syringe Sharing During a Single Injection Episode. <i>AIDS and Behavior</i> , 2011, 15, 75-85.	2.7	4
100	M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID. <i>Trials</i> , 2022, 23, 341.	1.6	4
101	Examining the Association Between Psychiatric Disorders and Cocaine Binges: Results From the COSMO Study. <i>Journal of Addiction Medicine</i> , 2018, 12, 136-142.	2.6	3
102	Prevalence, Characteristics, and Management of Chronic Noncancer Pain Among People Who Use Drugs: A Cross-Sectional Study. <i>Pain Medicine</i> , 2020, 21, 3205-3214.	1.9	3
103	Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs. <i>AIDS and Behavior</i> , 2020, 24, 2400-2408.	2.7	3
104	Portraying Persons Who Inject Drugs Recently Infected with Hepatitis C Accessing Antiviral Treatment: A Cluster Analysis. <i>Hepatitis Research and Treatment</i> , 2014, 2014, 1-7.	2.0	2
105	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. <i>Addiction</i> , 2017, 112, 1126-1127.	3.3	2
106	Estimates are not enough: scaling-up interventions to improve the health of people who inject drugs. <i>The Lancet Global Health</i> , 2017, 5, e1162-e1163.	6.3	2
107	Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection. <i>International Journal of Drug Policy</i> , 2021, 96, 103419.	3.3	2
108	The authors respond to "Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations". <i>Cmaj</i> , 2019, 191, E1085-E1085.	2.0	1

#	ARTICLE	IF	CITATIONS
109	Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective study. Canadian Liver Journal, 2020, 3, 358-371.	0.9	0